(Total Views: 590)
Posted On: 10/03/2023 1:42:57 PM
Post# of 156888
Re: Cassandra X #137712
I just sent this email to ABSCI -
Dear ABSCI,
ABSCI must be aware of Cytodyn Inc., also located in Vancouver, Washington, and their potential blockbuster humanized monoclonal antagonist for the CCR5 cell receptor.
Cytodyn is struggling, small pharma company presently because of bad past management but that isn't any negative reflection on the powerful efficacy of their drug, Leronlimab (PRO-140).
I believe both companies, ABSCI and Cytodyn would benefit massively from a collaboration.
Immune therapy by blockade of the CCR5 immune system receptor with Leronlimab has been shown to be exceptionally safe while being effective against dozens of morbidities of the most challenging kind - HIV, which directly exploits the CCR5 receptor, cancer, NASH, all auto-immune related diseases and, last but not least, Cytokine Storm.
Perhaps ABSCI know all about this and Cytodyn, I don't know. But if ABSCI doesn't, they are truely missing a golden opportunity in their backyard.
I am a shareholder in Cytodyn. I am also watching ABSCI's work. Good luck to you and I hope your R&D day goes very well tomorrow.
Sincerely,
Dear ABSCI,
ABSCI must be aware of Cytodyn Inc., also located in Vancouver, Washington, and their potential blockbuster humanized monoclonal antagonist for the CCR5 cell receptor.
Cytodyn is struggling, small pharma company presently because of bad past management but that isn't any negative reflection on the powerful efficacy of their drug, Leronlimab (PRO-140).
I believe both companies, ABSCI and Cytodyn would benefit massively from a collaboration.
Immune therapy by blockade of the CCR5 immune system receptor with Leronlimab has been shown to be exceptionally safe while being effective against dozens of morbidities of the most challenging kind - HIV, which directly exploits the CCR5 receptor, cancer, NASH, all auto-immune related diseases and, last but not least, Cytokine Storm.
Perhaps ABSCI know all about this and Cytodyn, I don't know. But if ABSCI doesn't, they are truely missing a golden opportunity in their backyard.
I am a shareholder in Cytodyn. I am also watching ABSCI's work. Good luck to you and I hope your R&D day goes very well tomorrow.
Sincerely,
(10)
(1)
